Search

Your search keyword '"Anacak, Y."' showing total 184 results
Start Over Author "Anacak, Y."
184 results on '"Anacak, Y."'

11. Effect Of Tumor Treating Fields And Radiotherapy Combination On Brain Tumor And Normal Brain Cell Lines

Author

Yalman, D., primary, Koylu, M., additional, Kayabasi, C., additional, Kamer, S., additional, Ozkan, E., additional, Yelken, B. Ozmen, additional, Tayfur, E., additional, Celebi, C., additional, Bilge, M.D., additional, Susluer, S. Yilmaz, additional, Parlak, C., additional, Bilge, M., additional, Anacak, Y., additional, and Gunduz, C., additional

Published
2020
Full Text
View/download PDF

14. The pain relief and recalcification results of radiotherapy for plasma cell tumors [Plasma hücreli tümörlerde radyoterapinin ağrı kesici ve rekalsifikasyon etkisi]

Author

Sert F., Kamer S., Saydam, G.., Anacak Y., and Ege Üniversitesi

Subjects
Radiotherapy, Multiple myeloma, Pain relief, Recalcification, Plasmocytoma
Abstract

Multiple Myeloma (MM) and Solitary Plasmocytoma (SP) are given as Plasma Cell Neoplasms (PCNs). Radiotherapy (RT) is used for definitive and/or palliative purposes.We aimed to evaluate the role of RT upon pain relief,recalcification and local disease control for the patients with PCNs. From January 2009 to December 2016, total 80 patients were evaluated. Eleven (13.8%) patients were classified as SP, and 69 (86.3%) were as MM. The total treatment dose was 45 Gy with 1.8 Gy per fraction for the SP and total 30 Gy with 2.5- 3 Gy per fraction for the MM. Numerical Rating Pain Scale (NRS) was used for pain level detection and the international consensus on palliative RT criteria was used for recalcification level classification before and after RT. Prior to RT, 56 (70%) patients suffered from severe pain, 19 (23.8%) patients suffered from moderate pain and only 5 (6.3%) patients reported mild pain. After RT, complete pain relief was achieved in 59 (73.8%) and partial pain relief was reported remaining 14 (17.5%) patients. We identified some kind of radiologic recalcification response in 77 (96.3%) patients. Complete and partial radiological response was recorded in 41 (51.3%) and 36 (45%) patients, respectively. Complete recalcification response was seen in 9 of 11 (82%) SP patients and 32 of 69 (46%) MM patients. The difference of complete recalcification response rates between two groups was significant (p= 0.031).Local disease control was achieved in 75 (94%) patients. The time interval after RT and applied RT doses are important factors for recalcification effect. Unlikely, pain relief can be achieved regardless of dose level. It can be stated that treatment doses over 30 Gy with multiple fractions should be suggested for the patients in good general condition with a life expectancy of > 1year. © 2019, UHOD - Uluslararasi Hematoloji Onkoloji Dergisi. All rights reserved.

Published
2019

15. Primary extranodal lymphoma of the glands. Literature review and options for best practice in 2019

Author

Belkacemi Y, Sio TT, Colson-Durand L, Onal C, Villà S, Anacak Y, Krengli M, Thariat J, Ugurluer G, Miller RC, Mirimanoff RO, Ozsahin M, and To NH

Subjects
Radiation therapy, Lymphoma, Glands, Extranodal non-Hodgkinlymphoma, Rare cancer, Clinical practice, Rituximab
Abstract

Primary extranodal non-Hodgkin's lymphomas (EN-NHL) are a heterogeneous group of malignancies that involve numerous entities with significant difference in terms of tumor site locations, prognostic factors, biology expression, and therapeutic options. In the literature, many EN-NHL types were reported from limited series which only allowed narrow views for elucidating prognostic factors and defining the role of loco-regional therapies in the era of new systemic and biologically targeted therapies. The Rare Cancer Network (RCN), an international multidisciplinary consortium, has published a number of reports on several EN-NHL sites which included many gland locations. In this review, we will focus on the recent literature for a selected number of EN-NHL types in both exocrine and endocrine gland locations. We aim to provide renewed and clear messages for the best practice in 2019 for diagnosis, histopathology, treatments, and also their prognostic implications. We believe that better understanding of molecular and genetic characteristics of these particular diseases is crucial for an appropriate management in the era of personalized treatment developments.

Published
2019

16. Langerhans cell histiocytosis: Excellent local control with low dose radiotherapy [Langerhan hücreli histiositozis: Düşük doz radyoterapi ile mükemmel lokal kontrol]

Author

Kamer S.A., Kirakli E.K., Cetingul N., Kantar M., Saydam, G.., Anacak Y., and Ege Üniversitesi

Subjects
Radiotherapy, Local control, Langerhans cell histiocytosis
Abstract

Langerhans cell histiocytosis (LCH) is a rare disorder. Uncontrolled clonal proliferation of langerhans cells leads to a diversity of clinical manifestations. Low dose Radiotherapy (RT) is used mainly for osseous manifestations as a sole treatment or in combination with surgery/chemotherapy/steroids. Altough the mechanism of action of RT is an unresolved issue, it’s usually used in adjuvant/palliative settings, also as first-line local therapy with curative intent in unresectable or resectable cases in case surgery would result in functional compromise. This study is conducted to review indications, dose-fractionation schedules, clinical characteristics and outcomes of LCH patients received local RT mainly for osseous lesions. The medical records of biopsy proven all LCH patients referred to our center and treated with RT between 2000-2016 were evaluated retrospectively. Disease-free survival (DFS), local control and side effects were defined as study end-points. There was 35 patients, 21 of them were children. At presentation 65.7% had single systemsingle bone, 20% had single system-multiple bone, 15% had multisystem disease.Soft tissue extension were detected in 16 children, 4 adults (p= 0.013).Mean radiation dose was 10.8 Gy. Median follow-up from the date of biopsy was 105 months (range= 8-204) in children and 88 (range:31-245) in adults (log rank p:0.029).Complete response rate was 97%. 11 children and 1 adult experienced relapse (p= 0.05), median interval for relapse was 9months in children, 19months in adults. The most common relapse pattern was as single system-multiple bone (58.3%). Local control was 97.1%. Median disease free survival was 85 months. Low dose local RT seems to be effective and safe in multidisciplinary management of LCH. © 2019, UHOD - Uluslararasi Hematoloji Onkoloji Dergisi. All rights reserved.

Published
2019

20. Retrospective clinical and radiologic analysis of adult high-grade glioma recurrence after temozolomide-based radiochemotherapy [Yetişkin yüksek dereceli gliom olgularinin radyokemoterapi sonrasi yinelemelerinin klinik ve radyolojik değerlendirilmesi]

Author

Akbelen B., Kamer S., Calli C., Hoca S., Anacak Y., and Ege Üniversitesi

Subjects
Radiochemoterapy, Pseudoprogression, Recurrence, Temozolomide, Glioblastoma
Abstract

Background: The aim of this study was to evaluate the recurrence patterns and the times of recurrence after temozolomide-based radiochemotherapy for high grade gliomas. Methods: Magnetic resonance imaging (MRI), diffusion MRI, perfusion MRI, and MRI spectroscopy scans of 30 patients who were treated with radiotherapy concurrently with temozolomide chemotherapy between June 2009 and April 2012 were retrospectively evaluated. Central, in-field, marginal, and distant recurrences of progression were defined related to radiation therapy dose distribution (90% isodose line). Results: The overall survival (OS) rates of central recurrences at 1 year and 2 years were 78% and 25%, respectively (at a median of 16 months). The OS rate of in-field, marginal and distant recurrences at 1 year and 2 years were 100% and 40%, respectively (at a median of 24 months). The progression-free survival (PFS) rate of central recurrences at 1 year and 2 years were 21% and 0%, respectively (at a median of 5 months). The PFS rate of in-field, marginal and distant recurrences at 1 year and 2 years were 36% and 27%, respectively (at a median of 11 months). The PFS rate of pseudoprogression at 1 year and 2 years were 87% and 43% (range, 7-31 months). Conclusions: The survival of new in-field, marginal and distant recurrences are longer and these new lesions develop at a later time compared with central recurrences. Pseudoprogression predicts better response to temozolomide-based radiochemotherapy. Finally, the location of recurrence is determined as one of the prognostic factors for OS and PFS. © 2018, Ege University Press. All rights reserved.

Published
2017

21. Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network study

Author

Henke G, R.O. Mirimanoff, Hadassah Goldberg, Luciano Scandolaro, Van Houtte P, P. Poortmans, Jacques Bernier, Pellanda Af, Michel Bolla, Rutten H, Stephen Chan, Salvador Villà, A. Richetti, Kirkove C, De Bari B, Van Eijkeren M, Christine Landmann, Anacak Y, E. Deniaud-Alexandre, Szutowicz-Zielińska E, Marco Krengli, and Mahmut Ozsahin

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Multivariate analysis, medicine.medical_treatment, overall survival, Population, Brachytherapy, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Uterine leiomyosarcoma, local control, prognostic factors, radiotherapy, Internal medicine, Medicine, Stage (cooking), education, education.field_of_study, Univariate analysis, business.industry, Proportional hazards model, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Log-rank test, Radiation therapy, 030104 developmental biology, 030220 oncology & carcinogenesis, Original Article, business
Abstract

Objective Primary uterine leiomyosarcomas (ULMS) are rare, and the optimal treatment is controversial. We aimed to assess the outcome and prognostic factors in a multicenter population of women treated for primary ULMS. Methods We retrospectively collected data of 110 women treated in 19 institutions of the Rare Cancer Network (RCN). Inclusion criteria consisted of a pathology report confirming the diagnosis of ULMS, aged 18-80 years, complete International Federation of Gynecology and Obstetrics (FIGO) stage information, complete information on treatment, and a minimum follow-up of 6 months. Local control (LC) and locoregional control (LRC), overall survival (OS) and disease-free survival (DFS) rates were computed using the Kaplan-Meier method. Univariate analysis was implemented using the log rank test, and multivariate analysis using the Cox model. Results All patients underwent surgery. Seventy-five patients (68%) received adjuvant radiotherapy (RT), including brachytherapy in 18 (16%). Seventeen patients (15%) received adjuvant chemotherapy. Median follow-up was 58 (range, 6-240) months. Five-year OS and DFS rates were 50% and 34%, and LC and LRC rates were 88% and 72%, respectively. On multivariate analysis, independent favorable prognostic factors were younger age, FIGO stage I, small tumor size, previous uterine disease, and no vascular invasion for OS and DFS. FIGO stage was the only favorable factor influencing LRC. Adjuvant local or systemic treatments did not improve the outcomes. Eight patients treated with RT presented a grade 3 acute toxicity, and only one patient with grade 3 late toxicity. Conclusions In this large population of primary ULMS patients, we found good results in terms of LC and LRC. Nevertheless, OS remains poor, mainly due to the occurrence of distant metastases. An early diagnosis seemed to improve the prognosis of the patients. Adjuvant local or systemic treatments, or more aggressive surgical procedures such as the Wertheim procedure, did not seem to impact the outcome.

Published
2017

24. SIOP PODC Adapted treatment guidelines for low grade gliomas in low and middle income settings

Author

Hessissen, L, Parkes, J, Amayiri, N, Mushtaq, N, Sirachainan, N, Anacak, Y, Mitra, D, Figaji, A, Schouten-van Meeteren, A, Sullivan, M, Burger, H, Davidson, A, Bouffet, E, Bailey, S, Hessissen, L, Parkes, J, Amayiri, N, Mushtaq, N, Sirachainan, N, Anacak, Y, Mitra, D, Figaji, A, Schouten-van Meeteren, A, Sullivan, M, Burger, H, Davidson, A, Bouffet, E, and Bailey, S

Abstract

Effective treatment of children with low grade glioma (LGG) requires a functioning multi-disciplinary team with adequate neurosurgical, neuroradiological, pathological, radiotherapy and chemotherapy facilities and personnel. In addition, the treating centre should have the capacity to manage a variety of LGG and treatment-associated complications. These requirements have made it difficult for many centers in low and middle-income countries (LMIC) to offer effective treatment and follow up. This article provides management recommendations for children with LGG according to the level of facilities available.

Published
2017

26. Prognostic significance of Bcl-2, C-Myc, survivin and tumor grade in synovial sarcoma [Sinovyal sarkom olgulari{dotless}nda Bcl-2, C-Myc, survivin ve tümör derecesinin prognostik degeri]

Author

Demir D., Yaman B., Anacak Y., Keçeci B., Kandiloglu G., Akalin T., and Ege Üniversitesi

Subjects
ComputingMilieux_MANAGEMENTOFCOMPUTINGANDINFORMATIONSYSTEMS, ComputingMethodologies_PATTERNRECOGNITION, Soft tissue neoplasm, ComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKS, Bcl-2, Myc, InformationSystems_MISCELLANEOUS, Prognosis, Immunohistochemistry
Abstract

PubMed ID: 24448706, Objective: We aimed to determine the prognostic value of bcl-2, c-myc and survivin in synovial sarcoma cases and to evaluate the relationship between the conventional morphological findings with prognosis. Material and Method: In this study, we evaluated 81 synovial sarcoma cases referred to our tertiary tumor center during a period of 20 years. We applied bcl-2, c-myc and survivin immunohistochemically and investigated the relationship with prognosis for those 65 cases with follow-up. The relationship between the conventional morphological findings (mitosis, necrosis, grade) with prognosis was also investigated. Results: Five-year disease free survival rate was 44% and ten-year progression free survival rate was 38%, reflecting the aggressive behavior of synovial sarcoma. Tumor grade (according to FNCLCC) was the most significant prognostic input in this study. We obtained a significant difference between grade II (40 cases) and grade III (24 cases) group regarding progression-free survival and overall survival (p

Published
2014

27. Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network

Author

Weber, D.C., Wang, Y., Miller, R., Villa, S., Zaucha, R., Pica, A., Poortmans, P.M.P., Anacak, Y., Ozygit, G., Baumert, B., Haller, G., Preusser, M., Li, J., Weber, D.C., Wang, Y., Miller, R., Villa, S., Zaucha, R., Pica, A., Poortmans, P.M.P., Anacak, Y., Ozygit, G., Baumert, B., Haller, G., Preusser, M., and Li, J.

Abstract

Item does not contain fulltext, BACKGROUND: Spinal myxopapillary ependymomas (MPEs) are slowly growing ependymal gliomas with preferential manifestation in young adults. The aim of this study was to assess the outcome of patients with MPE treated with surgery, radiotherapy (RT), and/or chemotherapy. METHODS: The medical records of 183 MPE patients (male: 59%) treated at the MD Anderson Cancer Center and 11 institutions from the Rare Cancer Network were retrospectively reviewed. Mean patient' age at diagnosis was 35.5 +/- 15.8 years. Ninety-seven (53.0%) patients underwent surgery without RT, and 86 (47.0%) were treated with surgery and/or RT. Median RT dose was 50.4 Gy. Median follow-up was 83.9 months. RESULTS: Fifteen (8.2%) patients died, 7 of unrelated cause. The estimated 10-year overall survival was 92.4% (95% CI: 87.7-97.1). Treatment failure was observed in 58 (31.7%) patients. Local failure, distant spinal relapse, and brain failure were observed in 49 (26.8%), 17 (9.3%), and 11 (6.0%) patients, respectively. The estimated 10-year progression-free survival was 61.2% (95% CI: 52.8-69.6). Age (<36 vs >/=36 y), treatment modality (surgery alone vs surgery and RT), and extent of surgery were prognostic factors for local control and progression-free survival on univariate and multivariate analysis. CONCLUSIONS: In this series, treatment failure of MPE occurred in approximately one third of patients. The observed recurrence pattern of primary spinal MPE was mainly local, but a substantial number of patients failed nonlocally. Younger patients and those not treated initially with adjuvant RT or not undergoing gross total resection were significantly more likely to present with tumor recurrence/progression.

Published
2015

28. Midplane dose determination and verification of calculated doses in total body irradiation [Tüm vücut i{dotless}şi{dotless}nlamalari{dotless}nda orta hat dozlari{dotless}ni{dotless}n belirlenmesi ve hesaplanan dozlari{dotless}n dogrulanmasi{dotless}]

Author

Özdemir Ö., Hoca S., Olacak N., Özkök S., Kamer S., Anacak Y., and Ege Üniversitesi

Subjects
In-vivo dosimetry, Thermoluminescence dosimetry, Total body irradiation
Abstract

To compare calculated and measured doses for different regions of anthropomorphic phantom and patients using ion chamber and thermoluminescence dosimetry (TLD) for total body irradiation. METHODS Measurements were done for lateral fields with 6 MV, gantry 82°, 40×40 cm2 field and 400 cm source-axis distance (SAD). Entrance-exit and midline doses were measured on anthropomorphic phantom by TLD and entrance-exit doses were measured by TLD and ion chamber on patients. RESULTS For anthropomorphic phantom measurements differences between calculated and measured entrance-exit doses of head, neck, shoulder, lung and thick pelvis were 0.8%, 2.7%, 26.4%, 4.4% and 4.9% and for midline doses were 1.6%, 1.6%, 6.3%, -1.4% and 7.4% respectively. For patients; TLD differences were within -4.13% ile 6.7%, -3.3% ile 3.9%, 5.1% ile 16.6%, -7.8% ile 2.4%, and 3.6% ile 7.1% respectively. For thick pelvis measurements with ion chamber differences were within %0.1-1.9. CONCLUSION Total body irradiation is being applied in limit values in our clinic. © 2013 Association of Oncology.

Published
2013

30. Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network

Author

Weber, D. C., primary, Wang, Y., additional, Miller, R., additional, Villa, S., additional, Zaucha, R., additional, Pica, A., additional, Poortmans, P., additional, Anacak, Y., additional, Ozygit, G., additional, Baumert, B., additional, Haller, G., additional, Preusser, M., additional, and Li, J., additional

Published
2014
Full Text
View/download PDF

33. HIGH GRADE GLIOMAS AND DIPG

Author

Classen, C. F., primary, William, D., additional, Linnebacher, M., additional, Farhod, A., additional, Kedr, W., additional, Elsabe, B., additional, Fadel, S., additional, Van Gool, S., additional, De Vleeschouwer, S., additional, Koks, C., additional, Garg, A., additional, Ehrhardt, M., additional, Riva, M., additional, Agostinis, P., additional, Graf, N., additional, Yao, T.-W., additional, Yoshida, Y., additional, Zhang, J., additional, Ozawa, T., additional, James, D., additional, Nicolaides, T., additional, Kebudi, R., additional, Cakir, F. B., additional, Gorgun, O., additional, Agaoglu, F. Y., additional, Darendeliler, E., additional, Al-Kofide, A., additional, Al-Shail, E., additional, Khafaga, Y., additional, Al-Hindi, H., additional, Dababo, M., additional, Haq, A. U., additional, Anas, M., additional, Barria, M. G., additional, Siddiqui, K., additional, Hassounah, M., additional, Ayas, M., additional, van Zanten, S. V., additional, Jansen, M., additional, van Vuurden, D., additional, Huisman, M., additional, Vugts, D., additional, Hoekstra, O., additional, van Dongen, G., additional, Kaspers, G., additional, Cockle, J., additional, Ilett, E., additional, Scott, K., additional, Bruning-Richardson, A., additional, Picton, S., additional, Short, S., additional, Melcher, A., additional, Benesch, M., additional, Warmuth-Metz, M., additional, von Bueren, A. O., additional, Hoffmann, M., additional, Pietsch, T., additional, Kortmann, R.-D., additional, Eyrich, M., additional, Rutkowski, S., additional, Fruhwald, M. C., additional, Faber, J., additional, Kramm, C., additional, Porkholm, M., additional, Valanne, L., additional, Lonnqvist, T., additional, Holm, S., additional, Lannering, B., additional, Riikonen, P., additional, Wojcik, D., additional, Sehested, A., additional, Clausen, N., additional, Harila-Saari, A., additional, Schomerus, E., additional, Thorarinsdottir, H. K., additional, Lahteenmaki, P., additional, Arola, M., additional, Thomassen, H., additional, Saarinen-Pihkala, U. M., additional, Kivivuori, S.-M., additional, Buczkowicz, P., additional, Hoeman, C., additional, Rakopoulos, P., additional, Pajovic, S., additional, Morrison, A., additional, Bouffet, E., additional, Bartels, U., additional, Becher, O., additional, Hawkins, C., additional, Gould, T. W. A., additional, Rahman, C. V., additional, Smith, S. J., additional, Barrett, D. A., additional, Shakesheff, K. M., additional, Grundy, R. G., additional, Rahman, R., additional, Barua, N., additional, Cronin, D., additional, Gill, S., additional, Lowisl, S., additional, Hochart, A., additional, Maurage, C.-A., additional, Rocourt, N., additional, Vinchon, M., additional, Kerdraon, O., additional, Escande, F., additional, Grill, J., additional, Pick, V. K., additional, Leblond, P., additional, Burzynski, G., additional, Janicki, T., additional, Burzynski, S., additional, Marszalek, A., additional, Ramani, N., additional, Zaky, W., additional, Kannan, G., additional, Morani, A., additional, Sandberg, D., additional, Ketonen, L., additional, Maher, O., additional, Corrales-Medina, F., additional, Meador, H., additional, Khatua, S., additional, Brassesco, M., additional, Delsin, L., additional, Roberto, G., additional, Silva, C., additional, Ana, L., additional, Rego, E., additional, Scrideli, C., additional, Umezawa, K., additional, Tone, L., additional, Kim, S. J., additional, Kim, C.-Y., additional, Kim, I.-A., additional, Han, J. H., additional, Choi, B.-S., additional, Ahn, H. S., additional, Choi, H. S., additional, Haque, F., additional, Layfield, R., additional, Grundy, R., additional, Gandola, L., additional, Pecori, E., additional, Biassoni, V., additional, Schiavello, E., additional, Chiruzzi, C., additional, Spreafico, F., additional, Modena, P., additional, Bach, F., additional, Pignoli, E., additional, Massimino, M., additional, Drogosiewicz, M., additional, Dembowska-Baginska, B., additional, Jurkiewicz, E., additional, Filipek, I., additional, Perek-Polnik, M., additional, Swieszkowska, E., additional, Perek, D., additional, Bender, S., additional, Jones, D. T., additional, Warnatz, H.-J., additional, Hutter, B., additional, Zichner, T., additional, Gronych, J., additional, Korshunov, A., additional, Eils, R., additional, Korbel, J. O., additional, Yaspo, M.-L., additional, Lichter, P., additional, Pfister, S. M., additional, Yadavilli, S., additional, Becher, O. J., additional, Kambhampati, M., additional, Packer, R. J., additional, Nazarian, J., additional, Lechon, F. C., additional, Fowkes, L., additional, Khabra, K., additional, Martin-Retortillo, L. M., additional, Marshall, L. V., additional, Vaidya, S., additional, Koh, D.-M., additional, Leach, M. O., additional, Pearson, A. D., additional, Zacharoulis, S., additional, Schrey, D., additional, Barone, G., additional, Panditharatna, E., additional, Stampar, M., additional, Siu, A., additional, Gordish-Dressman, H., additional, Devaney, J., additional, Hwang, E. I., additional, Chung, A. H., additional, Mittapalli, R. K., additional, Elmquist, W. F., additional, Castel, D., additional, Debily, M.-A., additional, Philippe, C., additional, Truffaux, N., additional, Taylor, K., additional, Calmon, R., additional, Boddaert, N., additional, Le Dret, L., additional, Saulnier, P., additional, Lacroix, L., additional, Mackay, A., additional, Jones, C., additional, Puget, S., additional, Sainte-Rose, C., additional, Blauwblomme, T., additional, Varlet, P., additional, Entz-Werle, N., additional, Maugard, C., additional, Bougeard, G., additional, Nguyen, A., additional, Chenard, M. P., additional, Schneider, A., additional, Gaub, M. P., additional, Tsoli, M., additional, Vanniasinghe, A., additional, Luk, P., additional, Dilda, P., additional, Haber, M., additional, Hogg, P., additional, Ziegler, D., additional, Simon, S., additional, Monje, M., additional, Gurova, K., additional, Gudkov, A., additional, Zapotocky, M., additional, Churackova, M., additional, Malinova, B., additional, Zamecnik, J., additional, Kyncl, M., additional, Tichy, M., additional, Puchmajerova, A., additional, Stary, J., additional, Sumerauer, D., additional, Boult, J., additional, Vinci, M., additional, Perryman, L., additional, Box, G., additional, Jury, A., additional, Popov, S., additional, Ingram, W., additional, Eccles, S., additional, Robinson, S., additional, Emir, S., additional, Demir, H. A., additional, Bayram, C., additional, Cetindag, F., additional, Kabacam, G. B., additional, Fettah, A., additional, Li, J., additional, Jamin, Y., additional, Cummings, C., additional, Bamber, J., additional, Sinkus, R., additional, Nandhabalan, M., additional, Bjerke, L., additional, Burford, A., additional, von Bueren, A., additional, Baudis, M., additional, Clarke, P., additional, Collins, I., additional, Workman, P., additional, Olaciregui, N., additional, Mora, J., additional, Carcaboso, A., additional, Bullock, A., additional, Alonso, M., additional, de Torres, C., additional, Cruz, O., additional, Pencreach, E., additional, Moussalieh, F. M., additional, Guenot, D., additional, Namer, I., additional, Pollack, I., additional, Jakacki, R., additional, Butterfield, L., additional, Hamilton, R., additional, Panigrahy, A., additional, Potter, D., additional, Connelly, A., additional, Dibridge, S., additional, Whiteside, T., additional, Okada, H., additional, Ahsan, S., additional, Raabe, E., additional, Haffner, M., additional, Warren, K., additional, Quezado, M., additional, Ballester, L., additional, Eberhart, C., additional, Rodriguez, F., additional, Ramachandran, C., additional, Nair, S., additional, Quirrin, K.-W., additional, Khatib, Z., additional, Escalon, E., additional, Melnick, S., additional, Classen, C. F., additional, Hofmann, M., additional, Schmid, I., additional, Simon, T., additional, Maass, E., additional, Russo, A., additional, Fleischhack, G., additional, Becker, M., additional, Hauch, H., additional, Sander, A., additional, Grasso, C., additional, Berlow, N., additional, Liu, L., additional, Davis, L., additional, Huang, E., additional, Woo, P., additional, Tang, Y., additional, Ponnuswami, A., additional, Chen, S., additional, Huang, Y., additional, Hutt-Cabezas, M., additional, Dret, L., additional, Meltzer, P., additional, Mao, H., additional, Abraham, J., additional, Fouladi, M., additional, Svalina, M. N., additional, Wang, N., additional, Hulleman, E., additional, Li, X.-N., additional, Keller, C., additional, Spellman, P. T., additional, Pal, R., additional, Jansen, M. H. A., additional, Sewing, A. C. P., additional, Lagerweij, T., additional, Vuchts, D. J., additional, van Vuurden, D. G., additional, Caretti, V., additional, Wesseling, P., additional, Kaspers, G. J. L., additional, Cohen, K., additional, Pearl, M., additional, Kogiso, M., additional, Zhang, L., additional, Qi, L., additional, Lindsay, H., additional, Lin, F., additional, Berg, S., additional, Muscal, J., additional, Amayiri, N., additional, Tabori, U., additional, Campbel, B., additional, Bakry, D., additional, Aronson, M., additional, Durno, C., additional, Gallinger, S., additional, Malkin, D., additional, Qaddumi, I., additional, Musharbash, A., additional, Swaidan, M., additional, Al-Hussaini, M., additional, Shandilya, S., additional, McCully, C., additional, Murphy, R., additional, Akshintala, S., additional, Cole, D., additional, Macallister, R. P., additional, Cruz, R., additional, Widemann, B., additional, Salloum, R., additional, Smith, A., additional, Glaunert, M., additional, Ramkissoon, A., additional, Peterson, S., additional, Baker, S., additional, Chow, L., additional, Sandgren, J., additional, Pfeifer, S., additional, Popova, S., additional, Alafuzoff, I., additional, de Stahl, T. D., additional, Pietschmann, S., additional, Kerber, M. J., additional, Zwiener, I., additional, Henke, G., additional, Muller, K., additional, Sieow, N. Y.-F., additional, Hoe, R. H. M., additional, Tan, A. M., additional, Chan, M. Y., additional, Soh, S. Y., additional, Burrell, K., additional, Chornenkyy, Y., additional, Remke, M., additional, Golbourn, B., additional, Barzczyk, M., additional, Taylor, M., additional, Rutka, J., additional, Dirks, P., additional, Zadeh, G., additional, Agnihotri, S., additional, Hashizume, R., additional, Ihara, Y., additional, Andor, N., additional, Chen, X., additional, Lerner, R., additional, Huang, X., additional, Tom, M., additional, Solomon, D., additional, Mueller, S., additional, Petritsch, C., additional, Zhang, Z., additional, Gupta, N., additional, Waldman, T., additional, Dujua, A., additional, Co, J., additional, Hernandez, F., additional, Doromal, D., additional, Hegde, M., additional, Wakefield, A., additional, Brawley, V., additional, Grada, Z., additional, Byrd, T., additional, Chow, K., additional, Krebs, S., additional, Heslop, H., additional, Gottschalk, S., additional, Yvon, E., additional, Ahmed, N., additional, Cornilleau, G., additional, Paulsson, J., additional, Andreiuolo, F., additional, Guerrini-Rousseau, L., additional, Geoerger, B., additional, Vassal, G., additional, Ostman, A., additional, Parsons, D. W., additional, Trevino, L. R., additional, Gao, F., additional, Shen, X., additional, Hampton, O., additional, Kosigo, M., additional, Baxter, P. A., additional, Su, J. M., additional, Chintagumpala, M., additional, Dauser, R., additional, Adesina, A., additional, Plon, S. E., additional, Wheeler, D. A., additional, Lau, C. C., additional, Gielen, G., additional, Muehlen, A. z., additional, Kwiecien, R., additional, Wolff, J., additional, Lulla, R. R., additional, Laskowski, J., additional, Goldman, S., additional, Gopalakrishnan, V., additional, Fangusaro, J., additional, Kieran, M., additional, Fontebasso, A., additional, Papillon-Cavanagh, S., additional, Schwartzentruber, J., additional, Nikbakht, H., additional, Gerges, N., additional, Fiset, P.-O., additional, Bechet, D., additional, Faury, D., additional, De Jay, N., additional, Ramkissoon, L., additional, Corcoran, A., additional, Jones, D., additional, Sturm, D., additional, Johann, P., additional, Tomita, T., additional, Nagib, M., additional, Bendel, A., additional, Goumnerova, L., additional, Bowers, D. C., additional, Leonard, J. R., additional, Rubin, J. B., additional, Alden, T., additional, DiPatri, A., additional, Browd, S., additional, Leary, S., additional, Jallo, G., additional, Prados, M. D., additional, Banerjee, A., additional, Carret, A.-S., additional, Ellezam, B., additional, Crevier, L., additional, Klekner, A., additional, Bognar, L., additional, Hauser, P., additional, Garami, M., additional, Myseros, J., additional, Dong, Z., additional, Siegel, P. M., additional, Gump, W., additional, Ayyanar, K., additional, Ragheb, J., additional, Krieger, M., additional, Kiehna, E., additional, Robison, N., additional, Harter, D., additional, Gardner, S., additional, Handler, M., additional, Foreman, N., additional, Brahma, B., additional, MacDonald, T., additional, Malkin, H., additional, Chi, S., additional, Manley, P., additional, Bandopadhayay, P., additional, Greenspan, L., additional, Ligon, A., additional, Albrecht, S., additional, Ligon, K. L., additional, Majewski, J., additional, Jabado, N., additional, Cordero, F., additional, Halvorson, K., additional, Taylor, I., additional, Hutt, M., additional, Weingart, M., additional, Price, A., additional, Kantar, M., additional, Onen, S., additional, Kamer, S., additional, Turhan, T., additional, Kitis, O., additional, Ertan, Y., additional, Cetingul, N., additional, Anacak, Y., additional, Akalin, T., additional, Ersahin, Y., additional, Mason, G., additional, Ho, C., additional, Crozier, F., additional, Vezina, G., additional, Packer, R., additional, Hwang, E., additional, Gilheeney, S., additional, Millard, N., additional, DeBraganca, K., additional, Khakoo, Y., additional, Kramer, K., additional, Wolden, S., additional, Donzelli, M., additional, Fischer, C., additional, Petriccione, M., additional, Dunkel, I., additional, Afzal, S., additional, Fleming, A., additional, Larouche, V., additional, Zelcer, S., additional, Johnston, D. L., additional, Kostova, M., additional, Mpofu, C., additional, Decarie, J.-C., additional, Strother, D., additional, Lafay-Cousin, L., additional, Eisenstat, D., additional, Fryer, C., additional, Hukin, J., additional, Hsu, M., additional, Lasky, J., additional, Moore, T., additional, Liau, L., additional, Davidson, T., additional, Prins, R., additional, Hassal, T., additional, Baugh, J., additional, Kirkendall, J., additional, Doughman, R., additional, Leach, J., additional, Jones, B., additional, Miles, L., additional, Hargrave, D., additional, Jacques, T., additional, Savage, S., additional, Saunders, D., additional, Wallace, R., additional, Flutter, B., additional, Morgenestern, D., additional, Blanco, E., additional, Howe, K., additional, Lowdell, M., additional, Samuel, E., additional, Michalski, A., additional, Anderson, J., additional, Arakawa, Y., additional, Umeda, K., additional, Watanabe, K.-i., additional, Mizowaki, T., additional, Hiraoka, M., additional, Hiramatsu, H., additional, Adachi, S., additional, Kunieda, T., additional, Takagi, Y., additional, Miyamoto, S., additional, Venneti, S., additional, Santi, M., additional, Felicella, M. M., additional, Sullivan, L. M., additional, Dolgalev, I., additional, Martinez, D., additional, Perry, A., additional, Lewis, P. W., additional, Allis, D. C., additional, Thompson, C. B., additional, and Judkins, A. R., additional

Published
2014
Full Text
View/download PDF

34. Radiotherapy capacity in Europe - Authors' reply

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service de radiothérapie oncologique, Rosenblatt, E., Izewska, J., Anacak, Y., Pynda, Y., Scalliet, Pierre, Boniol, M., Autier, P., UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service de radiothérapie oncologique, Rosenblatt, E., Izewska, J., Anacak, Y., Pynda, Y., Scalliet, Pierre, Boniol, M., and Autier, P.

Published
2013

35. The essential role of radiotherapy in the treatment of merkel cell carcinoma: a study from the rare cancer network

Author

Ghadjar, P., Kaanders, J.H.A.M., Poortmans, P.M.P., Zaucha, R., Krengli, M., Lagrange, J.L., Ozsoy, O., Nguyen, T.D., Miralbell, R., Baize, A., Boujelbene, N., Collen, T., Scandolaro, L., Untereiner, M., Goldberg, H., Pesce, G.A., Anacak, Y., Friedrich, E.E., Aebersold, D.M., Beer, K.T., Ghadjar, P., Kaanders, J.H.A.M., Poortmans, P.M.P., Zaucha, R., Krengli, M., Lagrange, J.L., Ozsoy, O., Nguyen, T.D., Miralbell, R., Baize, A., Boujelbene, N., Collen, T., Scandolaro, L., Untereiner, M., Goldberg, H., Pesce, G.A., Anacak, Y., Friedrich, E.E., Aebersold, D.M., and Beer, K.T.

Abstract

Item does not contain fulltext, PURPOSE: To evaluate the role of postoperative radiotherapy (RT) in Merkel cell carcinoma (MCC). METHODS AND MATERIALS: A retrospective multicenter study was performed in 180 patients with MCC treated between February 1988 and September 2009. Patients who had had surgery alone were compared with patients who received surgery and postoperative RT or radical RT. Local relapse-free survival (LRFS), regional relapse-free survival (RRFS), and distant metastasis-free survival (DMFS) rates were assessed together with disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS) rates. RESULTS: Seventy-nine patients were male and 101 patients were female, and the median age was 73 years old (range, 38-93 years). The majority of patients had localized disease (n = 146), and the remaining patients had regional lymph node metastasis (n = 34). Forty-nine patients underwent surgery for the primary tumor without postoperative RT to the primary site; the other 131 patients received surgery for the primary tumor, followed by postoperative RT (n = 118) or a biopsy of the primary tumor followed by radical RT (n = 13). Median follow-up was 5 years (range, 0.2-16.5 years). Patients in the RT group had improved LRFS (93% vs. 64%; p < 0.001), RRFS (76% vs. 27%; p < 0.001), DMFS (70% vs. 42%; p = 0.01), DFS (59% vs. 4%; p < 0.001), and CSS (65% vs. 49%; p = 0.03) rates compared to patients who underwent surgery for the primary tumor alone; LRFS, RRFS, DMFS, and DFS rates remained significant with multivariable Cox regression analysis. However OS was not significantly improved by postoperative RT (56% vs. 46%; p = 0.2). CONCLUSIONS: After multivariable analysis, postoperative RT was associated with improved outcome and seems to be an important component in the multimodality treatment of MCC.

Published
2011

39. 2522

Author

Anacak, Y., primary, Miller, R., additional, Constantinou, N., additional, Mamusa, A., additional, Ozsahin, M., additional, Li, Y., additional, Epelbaum, R., additional, Lucas, A., additional, Kowalczyk, A., additional, and Bese, N., additional

Published
2006
Full Text
View/download PDF

40. 2655

Author

Meyer, J.J., primary, Anacak, Y., additional, and Marks, L.B., additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results